Emsam Deal Marks Bristol's Return To The Antidepressant Market

Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.